Extrait

•To demonstrate non-inferiority of 4 doses of Hib-MenCY-TT compared to 3 doses of PedvaxHIB,when co-administered with Prevnar 13 and Havrix,in terms of anti-PRP concentration Epoch 001:To demonstrate non-inferiority of •2 doses of Rotarix co-administered with Hib-MenCY-TT,Pediarix and Prevnar 13 compared to Rotarix co-administered with PedvaxHIB,Pediarix and Prevnar 13 in terms of Rotarix IgA GMCs •3 doses of Prevnar 13 co-administered with Hib-MenCY-TT,Rotarix and Pediarix compared to Prevnar 13 co-administered with PedvaxHIB,Rotarix and Pediarix in terms of S. pneumoniae GMCs Epoch 002:To demonstrate non-inferiority of •2 doses of Havrix when the 1st dose is co-administered with Hib-MenCY-TT and Prevnar 13 compared to Havrix when the 1st dose is co-administered with PedvaxHIB and Prevnar 13,at 12-15 months of age •4 doses of Prevnar 13 co-administered with Hib-MenCY-TT and Havrix compared to Prevnar 13 co-administered with PedvaxHIB and Havrix in terms of S. pneumoniae GMCs

Critère d'inclusion

• invasive diseases caused by Haemophilus influenzae type b (Hib) and Neisseria meningitidis serogroups C (MenC) and Y (MenY)